<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumour</z:e> cells typically exhibit a G(1) cell cycle arrest in response to the MEK1/2 [<z:chebi fb="0" ids="52290">mitogen</z:chebi>-activated protein kinase/ERK (extracellular-signal-regulated kinase) kinase 1/2] inhibitor selumetinib, but do not die, and thus they acquire resistance </plain></SENT>
<SENT sid="1" pm="."><plain>In the present study we examined the effect of combining selumetinib with the <z:chebi fb="0" ids="30153">BH3 </z:chebi>[BCL2 (B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> 2) homology domain 3]-mimetic BCL2 inhibitor <z:chebi fb="5" ids="53329">ABT</z:chebi>-263 </plain></SENT>
<SENT sid="2" pm="."><plain>Although either drug alone caused little <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> cell <z:hpo ids='HP_0011420'>death</z:hpo>, the two agents combined to cause substantial caspase-dependent cell <z:hpo ids='HP_0011420'>death</z:hpo> and inhibit long-term clonogenic survival of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> and <z:hpo ids='HP_0002861'>melanoma</z:hpo> cell lines with BRAF(V600E) or <z:mp ids='MP_0011356'>RAS</z:mp> mutations </plain></SENT>
<SENT sid="3" pm="."><plain>This cell <z:hpo ids='HP_0011420'>death</z:hpo> absolutely required BAX (BCL2-associated X protein) and was inhibited by RNAi (<z:chebi fb="40" ids="33697">RNA</z:chebi> interference)-mediated knockdown of BIM (BCL2-interacting mediator of cell <z:hpo ids='HP_0011420'>death</z:hpo>) in the BRAF(V600E)-positive COLO205 cell line </plain></SENT>
<SENT sid="4" pm="."><plain>When <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cell lines were treated with selumetinib plus <z:chebi fb="5" ids="53329">ABT</z:chebi>-263 we observed a striking reduction in the incidence of cells emerging with acquired resistance to selumetinib </plain></SENT>
<SENT sid="5" pm="."><plain>Similar results were observed when we combined <z:chebi fb="5" ids="53329">ABT</z:chebi>-263 with the BRAF(V600E)-selective inhibitor PLX4720, but only in cells expressing BRAF(V600E) </plain></SENT>
<SENT sid="6" pm="."><plain>Finally, <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells in which acquired resistance to selumetinib arises through BRAF(V600E) amplification remained sensitive to <z:chebi fb="5" ids="53329">ABT</z:chebi>-263, whereas selumetinib-resistant HCT116 cells (KRAS(G13D) amplification) were cross-resistant to <z:chebi fb="5" ids="53329">ABT</z:chebi>-263 </plain></SENT>
<SENT sid="7" pm="."><plain>Thus the combination of a BCL2 inhibitor and an ERK1/2 pathway inhibitor is synthetic lethal in ERK1/2-addicted <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> cells, delays the <z:hpo ids='HP_0003674'>onset</z:hpo> of acquired resistance and in some cases overcomes acquired resistance to selumetinib </plain></SENT>
</text></document>